clomipramine has been researched along with Skin Diseases in 4 studies
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.
Skin Diseases: Diseases involving the DERMIS or EPIDERMIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Some of the psychiatric disorders that are usually comorbid with dermatological disorders and respond to antidepressants include major depressive disorder, obsessive compulsive disorder, body dysmorphic disorder, social phobia and post-traumatic stress disorder usually secondary to trauma and abuse during early life." | 2.41 | The use of antidepressant drugs in dermatology. ( Gupta, MA; Guptat, AK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, H | 1 |
| Gupta, MA | 1 |
| Guptat, AK | 1 |
| Koo, JY | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ascending-Dose, Double-Blind, Placebo-Controlled, Bilateral Study of Intralesional Fluphenazine Decanoate in Psoriasis[NCT00356200] | Phase 2 | 10 participants (Actual) | Interventional | 2006-07-31 | Terminated (stopped due to Enrollment criteria met) | ||
| Ascending-Dose, Double-Blind, Placebo-Controlled, Study of Intralesional Fluphenazine Hydrochloride for Psoriasis[NCT00929578] | Phase 2 | 15 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 4 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis). (NCT00356200)
Timeframe: Baseline to week 4
| Intervention | mm (Mean) |
|---|---|
| Cohort 1, 10 ug/ml Fluphenazine Treated Lesion | -30 |
| Cohort 1, Placebo Treated Lesion | -27.2 |
| Cohort 2, 100 ug/ml Fluphenazine Treated Lesion | -18 |
| Cohort 2, Placebo Treated Lesion | -32.6 |
Change in score from 0-14 of target lesion disease activity based on scaling, erythema, and induration as determined by a physician assessor at week 4 compared to baseline (with 0 being no disease activity and 14 being maximum disease activity). (NCT00356200)
Timeframe: Baseline to week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Cohort 1, 10 ug/ml Fluphenazine Treated Lesion | -1 |
| Cohort 1, Placebo Treated Lesion | -0.8 |
| Cohort 2, 100 ug/ml Fluphenazine Treated Lesion | -0.4 |
| Cohort 2, Placebo Treated Lesion | -1.5 |
Actual change in target lesion score comparing 4 week score with baseline score. Improvement is positive, worsening is negative. Target lesions scores range from 0 (no disease) to 12 (severe disease), and are scored based on the sum of erythema (0-4), induration (0-4) and scale (0-4) scores. (NCT00929578)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -1.4 |
| Fluphenazine | -1.4 |
Visual Analog Scale (VAS) score for pruritus. Subjective measurement of pruritus on an analog scale with a single mark denoting self-perceived pruritus: Minimum 0mm for no itch, Maximum 100mm for worst itch imaginable. Scores are measured in millimeters. This secondary outcome is a percentage improvement from baseline score for pruritus. Improvement is negative, worsening is positive. (NCT00929578)
Timeframe: 4 weeks
| Intervention | percentage of baseline pruritus (Mean) |
|---|---|
| Placebo | 0.86 |
| Fluphenazine | -2.16 |
Number of participants with fluphenazine serum levels > 0.200ng/ml, at baseline, 2 hours post dose and 1 week post dose. (NCT00929578)
Timeframe: 1 week
| Intervention | participants (Number) |
|---|---|
| Baseline | 0 |
| 2 Hours Post Dose | 2 |
| 1 Week Post Dose | 2 |
adverse events will be recorded and monitored. Adverse events will be noted in a separate chart. (NCT00929578)
Timeframe: 8 weeks
| Intervention | All Study Participant (Number) |
|---|---|
| All Study Participants | 12 |
1 review available for clomipramine and Skin Diseases
| Article | Year |
|---|---|
The use of antidepressant drugs in dermatology.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Mental | 2001 |
The use of antidepressant drugs in dermatology.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Mental | 2001 |
The use of antidepressant drugs in dermatology.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Mental | 2001 |
The use of antidepressant drugs in dermatology.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Mental | 2001 |
3 other studies available for clomipramine and Skin Diseases
| Article | Year |
|---|---|
Psychogenic excoriation responding to fluoxetine: a case report.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Behavior Therapy; Clomipramine; Compulsive Beh | 2008 |
The use of psychotropic medications in clinical dermatology.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Clomipramine; Humans; Neurotic Dis | 1992 |
Treating compulsive behaviors in dermatology.
Topics: Clomipramine; Compulsive Behavior; Humans; Neurodermatitis; Prurigo; Skin Diseases | 1991 |